Certara’s COVID-19 Vaccine Model
Established in 1963, the R&D 100 Awards is the only S&T (science and technology) awards competition that recognizes new commercial products, technologies, and materials for their technological significance that are available for sale or license. The R&D 100 Awards, celebrating the program's 60th Anniversary this year, has long been a benchmark of excellence for industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology. This 2022 R&D 100 winner is listed below, along with its respective category.
Category: Software/Services
Developers: Certara Rana Healthcare Solutions LLC
United States
Product Description:Certara’s COVID-19 Vaccine Model employs biosimulation (computer-aided modeling and simulation integrated with pharmaceutical and biological science) and virtual populations to facilitate global vaccine decision-making. It addresses important COVID-19 vaccine questions such as expected duration of antibody response, whether elderly people should get a larger dose, and optimal timing between doses.
Developers: Certara Rana Healthcare Solutions LLC
United States
Product Description:Certara’s COVID-19 Vaccine Model employs biosimulation (computer-aided modeling and simulation integrated with pharmaceutical and biological science) and virtual populations to facilitate global vaccine decision-making. It addresses important COVID-19 vaccine questions such as expected duration of antibody response, whether elderly people should get a larger dose, and optimal timing between doses.
The COVID-19 Vaccine Model shows in graphical form the antibody response (or how many antibodies a person produces against the COVID-19 virus) when the second vaccine dose is given several weeks after the first dose. Antibody response is used as a surrogate for efficacy in vaccinology and is considered the best biomarker. This approach can show when the maximum antibody response is generated by the second vaccine dose and at what interval after the first dose that response begins to diminish. That information is used to guide the next clinical steps. In the Daiichi Sankyo COVID-19 vaccine example above, the optimal dosing interval was considered to be 28 days. Certara’s COVID-19 Vaccine Model also suggested that the maximum number of memory B cells would be generated at about 28 days after the first vaccination.